Regine Buffels
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.
Journal: European journal of neurology
Published: November 11, 2025
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Journal: Journal of neurology
Published: November 10, 2023
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Journal: Frontiers in neurology
Published: December 02, 2022
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 17, 2022
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Journal: European journal of neurology
Published: August 18, 2021
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: July 30, 2020
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Journal: Journal of neurology
Published: December 07, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: November 22, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026